GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Avacta Group PLC (OTCPK:AVCTF) » Definitions » Short Percentage of Float

AVCTF (Avacta Group) Short Percentage of Float


View and export this data going back to 2015. Start your Free Trial

What is Avacta Group Short Percentage of Float?

Short Percentage of Float is the percentage of shares shorted compared to the float.

Due to the license agreement change with our data vendor, Short Interest related data is no longer available on GuruFocus website.


Competitive Comparison of Avacta Group's Short Percentage of Float

For the Biotechnology subindustry, Avacta Group's Short Percentage of Float, along with its competitors' market caps and Short Percentage of Float data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Avacta Group's Short Percentage of Float Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Avacta Group's Short Percentage of Float distribution charts can be found below:

* The bar in red indicates where Avacta Group's Short Percentage of Float falls into.


;
;

Avacta Group Business Description

Traded in Other Exchanges
Address
Unit 20, Ash Way, Thorp Arch Estate, West Yorkshire, Wetherby, GBR, LS23 7FA
Avacta Group PLC is a United Kingdom-based biotechnology company. The company offers its products through three segments that are Diagnostics, Therapeutics, and Animal Health. The company is developing novel cancer immunotherapies combining its two proprietary platforms Affimer biotherapeutics and precision tumor-targeted chemotherapy. The company operates in the United Kingdom, France, South Korea, Rest of Europe, Asia, and North America.

Avacta Group Headlines

From GuruFocus

Avacta Announces License Agreement With POINT Biopharma Inc.

By Business Wire Business Wire 01-07-2021

Avacta and Mologic Announce Commercial Partnership

By Business Wire Business Wire 02-08-2021

Avacta Announces Collaboration Agreement With Bruker

By Business Wire Business Wire 01-28-2021

LG Chem Renews License Triggering Payment to Avacta

By Business Wire Business Wire 06-30-2022

Avacta Appoints Dr Christina Coughlin as Non-Executive Director

By Business Wire Business Wire 03-21-2022

Avacta Group plc Signs License Agreement With Astrea Bioseparations

By Business Wire Business Wire 12-21-2020

Avacta's Diagnostic Division Achieves ISO 13485 Certification

By Business Wire Business Wire 07-14-2021